Daisuke Arai - Concepedia

Author

Daisuke Arai

Also Known As

Consuelo D. Quinto-Cortés, D. Arai, DAISUKE ARAI, Daisuke ARAI, Daisuke Arai, Fumitake Saito, Genotek COVID-19 study, Rie Baba, Tomoyuki Uchida

179

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Keio University Saiseikai Utsunomiya hospital National Hospital Organization Keio University Hospital Saiseikai Kumamoto Hospital

About

Daisuke Arai is an author at Keio University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	565
2	Engineering	3	3	41
3	Natural Sciences	1	1	12
4	Public Health	1	1	13
5	Applied Physics	1	1	12

Daisuke Arai

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Molecular Cancer Research PathologyTumor BiologyOncologySignaling PathwayReceptor Tyrosine Kinase	2013	205
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, Oncotarget	2015	157
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT) Yoshihiko Sakata, Shinya Sakata, Yuko Oya, European Journal of Cancer Real-world SettingMedicinePathologyFirst-line TreatmentMolecular Oncology	2021	81
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, Molecular Cancer Research	2016	71
Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior Ahmed E. Hegab, Daisuke Arai, Jingtao Gao, Stem Cell Research	2015	63
Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer Cells Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, Molecular Cancer Therapeutics	2015	61
Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis Keigo Kobayashi, Ichiro Nakachi, Katsuhiko Naoki, Clinical Lung Cancer MedicineRetrospective Multicenter AnalysisImmune Checkpoint InhibitorReal-world EfficacyCancer Treatment	2018	53
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations Shinnosuke Ikemura, Hiroyuki Yasuda, Shingo Matsumoto, Proceedings of the National Academy of Sciences	2019	53
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON) Go Saito, Yuko Oya, Yoshihiko Taniguchi, Lung Cancer Durvalumab Consolidation TherapyMedicineMetronomic TherapyReal-world SurveyBronchial Neoplasm	2021	53
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer Keiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, Lung Cancer OncologyMedicinePathologyFibroblast Growth FactorPoor Prognosis	2013	49

Page 1